Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06923228 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis
A Phase 2 study, sponsored by CAGE Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT06923228 is a Phase 2 study that has completed, run by CAGE Bio. The registered enrollment target is 3 participants.
The verdict
NCT06923228, a Phase 2 study, has completed, sponsored by CAGE Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if drug CGB-500 works to treat atopic dermatitis in subjects 12 years of age or older. It will also learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 decrease the severity of atopic dermatitis on the skin? What medical problems do participants have when taking drug CGB-500? Researchers will compare CGB-500 to a an approved product (1.5% ruxolitinib) to see if CGB-500 works to treat atopic dermatitis. Participants will: Apply CGB-500 and ruxolitinib to different locations on their body twice a day for four weeks. Visit the clinic six times for checkups and tests Keep a diary of their symptoms and when they apply the product
Interventions
- DRUG CGB-500 Ointment with 1% tofacitinib
- DRUG Ruxolitinib 1.5% Cream QD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06923228
The ClinicalTrials.gov registry entry for NCT06923228 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CAGE Bio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CGB-500 Ointment with 1% tofacitinib is the first listed.
NCT06923228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06923228 about?
NCT06923228 is a clinical study titled "A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis". The goal of this clinical trial is to learn if drug CGB-500 works to treat atopic dermatitis in subjects 12 years of age or older. It will also learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 decrease the severity of atopic dermatitis on the skin? What medi...
What is the current status of trial NCT06923228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2025-04-21. Estimated completion is 2025-09-30.
What interventions are being tested in trial NCT06923228?
The interventions under investigation include: CGB-500 Ointment with 1% tofacitinib (DRUG), Ruxolitinib 1.5% Cream QD (DRUG).
Who is sponsoring clinical trial NCT06923228?
This trial is sponsored by CAGE Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.